Immune cell therapy for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new kind of immune cell treatment (engineered immune effectors) for people with advanced ovarian cancer (stages II–IV). The goal is to see if these specially made cells can help fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 10 years old.
- Your ovarian cancer must be a high-risk type, at stage II, III, or IV.
- You must not have had a previous treatment called "adoptive T cell therapy."
- Your blood counts (white cells and platelets) must be at a safe level.
- Your kidney and liver function must be within normal limits (checked by blood tests).
- You must not be pregnant, and you must use effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a lab-made immune cell treatment designed to recognize ovarian cancer and attack it. It may help people with high-risk ovarian cancer who still need effective options.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
This study tests two new experimental drugs (XmAb541 and XmAb808) designed to fight advanced ovarian cancer by activating your immune system. You'll be closely monitored to see how safe the drugs are and how your body tolerates them.
This trial tests a new approach using your own immune cells (tumor-infiltrating lymphocytes) that have been modified to work better, followed by a combination of oral chemo and immunotherapy. It's for people with ovarian cancer that has come back after standard treatment.
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
This trial tests a new type of immune therapy called CAR T-cells (SCT-001) for ovarian cancer that has returned or isn't responding to standard treatments. The cells are engineered to find and attack cancer cells that have a specific marker (TAG-72) on their surface.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.